{
    "patient": {
        "Name": "Scott Patton",
        "DateOfBirth": "1958-01-08",
        "Sex": "Male",
        "Diagnosis": "Follicular thyroid cancer",
        "BodyPart": "Thyroid",
        "Physician": "Dr. Melissa Cooper",
        "TreatingInstitution": "Miller, Schwartz and Watkins"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Thyroid",
            "CollectedDate": "2023-11-19",
            "ReceivedDate": "2023-11-19",
            "TumorPercentage": "22%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-11-26",
            "ReceivedDate": "2023-11-26"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "APC",
                "DNA Alteration": "c.3920T>A",
                "GeneMutation": "p.I1307K Spliceregionvariant-LOF",
                "VariantAlleleFraction": "23.13%"
            },
            {
                "Gene": "KLF4",
                "DNA Alteration": "c.1225A>C",
                "GeneMutation": "p.K409Q Spliceregionvariant-GOF",
                "VariantAlleleFraction": "23.52%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.K409Q Nonsense-GOF",
                "VariantAlleleFraction": "27.29%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.N159Y Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.93%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Nonsense-GOF",
                "VariantAlleleFraction": "12.36%"
            },
            {
                "Gene": "ALK",
                "DNA Alteration": "c.3185A>T",
                "GeneMutation": "p.V49M Nonsense-GOF",
                "VariantAlleleFraction": "11.14%"
            },
            {
                "Gene": "TEK",
                "DNA Alteration": "c.1354A>G",
                "GeneMutation": "p.F1174C Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "9.03%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": []
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "44 m/Mb",
            "Tmbpercentile": "80%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "CALR",
                "DNA Alteration": "c.1154_1155insTTGTC",
                "GeneMutation": "p.K385fs*47 Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "12.36%"
            },
            {
                "Gene": "GNAS",
                "DNA Alteration": "c.602G>A",
                "GeneMutation": "p.R160C Frameshift-GOF",
                "VariantAlleleFraction": "15.94%"
            },
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A374E Spliceregionvariant-LOF",
                "VariantAlleleFraction": "5.84%"
            },
            {
                "Gene": "MAP2K2",
                "DNA Alteration": "c.383C>T",
                "GeneMutation": "p.P128L Frameshift-GOF",
                "VariantAlleleFraction": "5.07%"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R1012X Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.67%"
            },
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "8.96%"
            },
            {
                "Gene": "KRAS",
                "DNA Alteration": "c.35_36delinsAA",
                "GeneMutation": "p.G12N Spliceregionvariant-LOF",
                "VariantAlleleFraction": "9.53%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Frameshift-GOF",
                "VariantAlleleFraction": "5.99%"
            },
            {
                "Gene": "ARHGAP45",
                "DNA Alteration": "c.416G>A",
                "GeneMutation": "p.R139H Nonsense-GOF",
                "VariantAlleleFraction": "7.51%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A572G Frameshift-LOF",
                "VariantAlleleFraction": "3.44%"
            },
            {
                "Gene": "KLF1",
                "DNA Alteration": "c.115A>C",
                "GeneMutation": "p.A298P Frameshift-GOF",
                "VariantAlleleFraction": "1.92%"
            },
            {
                "Gene": "DNMT3A",
                "DNA Alteration": "c.2711C>T",
                "GeneMutation": "p.P904L Spliceregionvariant-LOF",
                "VariantAlleleFraction": "1.1%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "PAX5",
        "BRCA2"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "APC",
                "DNA Alteration": "c.3920T>A",
                "GeneMutation": "p.I1307K Spliceregionvariant-LOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "23.13%"
            },
            {
                "Gene": "KLF4",
                "DNA Alteration": "c.1225A>C",
                "GeneMutation": "p.K409Q Spliceregionvariant-GOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "23.52%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.K409Q Nonsense-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "27.29%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.N159Y Spliceregionvariant-LOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "3.93%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Nonsense-GOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "12.36%"
            },
            {
                "Gene": "ALK",
                "DNA Alteration": "c.3185A>T",
                "GeneMutation": "p.V49M Nonsense-GOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "11.14%"
            },
            {
                "Gene": "TEK",
                "DNA Alteration": "c.1354A>G",
                "GeneMutation": "p.F1174C Missensevariant(exon2)-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "9.03%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-11-16"
    },
    "other": {
        "ReportId": "5259",
        "ReportDate": "2023-11-19",
        "SignedBy": "Melissa Cooper",
        "Supervisor": "Dr. Adrian Calhoun"
    }
}